Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Revenue: 2021-2024

Historic Revenue for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to $26.2 million.

  • Amylyx Pharmaceuticals' Revenue fell 79.28% to $26.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $116.3 million, marking a year-over-year decrease of 73.04%. This contributed to the annual value of $114.3 million for FY2024, which is 73.52% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Revenue of $26.2 million as of Q4 2024, which was up 6,205.05% from $416,000 recorded in Q3 2024.
  • In the past 5 years, Amylyx Pharmaceuticals' Revenue registered a high of $126.6 million during Q4 2023, and its lowest value of $285,000 during Q3 2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Revenue value was $55.6 million (recorded in 2022), while the average stood at $57.5 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Revenue skyrocketed by 20,350.46% in 2023 and then crashed by 99.63% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Revenue (Quarterly) stood at $285,000 in 2021, then soared by 91.93% to $26.6 million in 2022, then surged by 376.75% to $126.6 million in 2023, then plummeted by 79.28% to $26.2 million in 2024.
  • Its Revenue stands at $26.2 million for Q4 2024, versus $416,000 for Q3 2024 and $1.0 million for Q2 2024.